12:00 AM
Oct 06, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Taranabant: Development discontinued

Merck said it ended development of taranabant to treat obesity after pooled data from a Phase III program showed "efficacy and adverse events were dose related, with greater efficacy and more adverse events in the higher doses." The pharma said it will discontinue 5 ongoing Phase III extension studies evaluating long-term use...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >